Moflaxa (Moxifloxacin)

• Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections affecting the respiratory, skin and intra‑abdominal systems.
• Community‑acquired pneumonia: eradicates the causative bacteria, leading to clinical improvement and resolution of infection.
• Acute bacterial sinusitis: eliminates the pathogenic microorganisms, reducing symptoms and preventing complications.
• Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth, improving airflow and reducing exacerbation severity.
• Skin and soft‑tissue infections: targets a broad range of Gram‑positive and Gram‑negative organisms, facilitating wound healing.
• Complicated intra‑abdominal infections: provides broad‑spectrum coverage against typical and atypical intra‑abdominal pathogens.

• Moxifloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. Inhibition of these enzymes prevents DNA strand separation, halting bacterial DNA synthesis and transcription, which leads to rapid bacterial cell death. The drug displays concentration‑dependent killing and a broad spectrum against Gram‑positive, Gram‑negative and atypical pathogens in clinical settings.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in many patients.
• Diarrhea: loose stools that are usually self‑limiting.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Dizziness: temporary sensation of light‑headedness.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon failure, most often in the Achilles tendon.
• QT interval prolongation: may precipitate ventricular arrhythmias.
• Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention.
• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Anaphylaxis: acute, potentially life‑threatening allergic response.
• Peripheral neuropathy: persistent sensory disturbances.

When prescribing Moxifloxacin, clinicians should consider several precautionary measures to minimize risk.

• Assess renal function: adjust dosing in severe impairment.
• Monitor cardiac status: watch for QT interval prolongation, especially in patients with cardiac disease.
• Avoid use in patients with known hypersensitivity to fluoroquinolones.
• Use with caution in elderly: increased risk of tendon injury and peripheral neuropathy.
• Review concomitant medications: avoid drugs that also prolong QT interval.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Co‑administration with other QT‑prolonging agents (e.g., quinidine, macrolide antibiotics): heightened risk of cardiac arrhythmias.
• Antacids or supplements containing magnesium, aluminum, calcium, or iron: markedly reduce moxifloxacin absorption.
• Theophylline: increased plasma theophylline concentrations, raising toxicity risk.
• Warfarin: potentiation of anticoagulant effect, requiring closer INR monitoring.

Moderate Interactions (Monitor Closely)

• Corticosteroids: combined use may increase tendon rupture risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance central nervous system adverse effects.
• Cyclosporine: possible increase in moxifloxacin plasma levels.